摘要
目的 对照研究莫西沙星与左氧氟沙星治疗老年人呼吸道细菌感染的临床疗效及安全性。方法 将确诊为急性呼吸道感染老年患者86例随机分为治疗组和对照组，治疗组给予莫西沙星400mg口服，每日1次，对照组给予左氧氟沙星200mg口服，每日2次，疗程7～10天。结果 治疗组的综合疗效高于对照组（P〈0．01）；治疗组痊愈率为68．18％，有效率为95.45％。均显著高于时照组的33．33％和76．19％（P〈0．01）；治疗组在细菌清除率（93．54％）与药物敏感性（96．77％）方面优于对照组（72．41％和75．86％），差异有境计学意义（P〈0．05）；治疗组不良反应为4．55％，对照组为7．14％。结论 莫西沙星具有良好的安全性、耐受性及疗效，是治疗老年人呼吸道感染较为理想的抗菌药物。
Objective To compare the efficacy and safety of moxifloxacin and levofloxacin in treating respiratory tract bacterial infections in the senile patients. Methods Eighty-six senile patients with respiratory tract bacterial infections were randomly divided into two groups. The clinical trial group with moxifloxacin 400 mg once a day,orally for 7-10 clays and the control group with levofloxacin 200 mg twice a day for 7-10 days. Results The total clinical effective rate in the clinical trial group was significantly higher than that in the control group （ P 〈0.01）. The recovery rate of the clinical trial group （68.18%） and the effective rate （95.45 %） were significantly higher than that of the control group （33.33% and 76.19%, P 〈0. 01）. The clinical trial group was better than the control group at the eradication rates of pathogens （93.54% and 72.41 %） and sensitivity of drugs （96.77 % and 75.86%）, the difference had the statistical significance （ P 〈0.05）. The rate of adverse reaction was A. 55 % in the clinical trial group and 7.14 % in the control group, respectively. Conclusion Moxifloxacin is an effective and safe antibacterial drug in treating respiratory tract bacterial infections in the senile patients.
出处
《临床荟萃》
CAS
北大核心
2006年第12期853-855,共3页
Clinical Focus
关键词
呼吸道感染
老年人
莫西沙星
左氧氟沙星
respiratory tract bacterial infections
senility
moxifloxacin
levofloxacin
